NASDAQ · LQDAHealthcarePharmaceuticals

Liquidia financials

$70.69−4.05%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Dec 31
FY24
Dec 31
FY23
Dec 31
FY22
Dec 31
FY21
Dec 31
FY20
Dec 31
FY19
Dec 31
Revenue$158.3M$14.0M$17.5M$15.9M$12.9M$739.6K$8.1M
Gross profit$145.1M$8.1M$14.6M$13.1M$9.8M$501.9K$7.3M
Gross margin91.6%58.0%83.5%82.1%76.5%67.9%90.0%
Operating income-$51.4M-$121.3M-$73.4M-$38.8M-$33.8M-$59.1M-$46.8M
Net income-$68.9M-$128.3M-$78.5M-$41.0M-$34.6M-$59.8M-$47.6M
Net margin−43.5%−916.6%−448.9%−257.4%−269.0%−8080.1%−589.5%
Diluted EPS$-0.80$-1.63$-1.21$-0.67$-0.70$-1.76$-2.57
EBITDA-$49.8M-$119.1M-$71.2M-$35.1M-$28.2M-$56.0M-$44.3M
Operating cash flow-$35.7M-$93.4M-$41.6M-$28.6M-$29.0M-$53.6M-$48.3M
Free cash flow-$40.0M-$98.4M-$42.9M-$29.2M-$29.2M-$54.4M-$50.1M
Diluted shares86.1M78.7M65.0M61.0M49.7M33.9M18.5M

Balance sheet

Period endDec 31Dec 31Dec 31Dec 31Dec 31Dec 31
Cash & equivalents$190.7M$176.5M$83.7M$93.3M$57.5M$65.3M
Short-term investments$0.00$0.00$0.00$0.00——
Total debt$191.3M$113.3M$46.0M$20.2M$11.1M$11.5M
Total assets$327.9M$230.3M$118.3M$129.2M$93.7M$99.5M
Total liabilities$283.2M$150.9M$71.0M$38.8M$28.5M$28.4M
Shareholders' equity$44.7M$79.4M$47.3M$90.4M$65.3M$71.1M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology